Last checked at 2 Nov 2023 15:34
2 November 2023
Futura Medical plc
("Futura" or the "Company")
Eroxon Awarded "New Product of the Year, Healthcare" by Boots
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the pharmaceutical company developing innovative sexual health products, announces that Eroxon® has won the "New Product of the Year, Healthcare" category at the Boots Supplier Awards 2023, following its UK launch earlier this year. The award is further recognition for Futura's breakthrough treatment for erectile dysfunction ("ED") as it provides an alternative treatment option for the 4.3 million men in the UK experiencing symptoms*.
James Barder, Chief Executive Officer of Futura said: "Winning the "New Product of the Year, Healthcare" award at this year's Boots Supplier Awards is great recognition for Eroxon® by one of Britain's most trusted brands. Eroxon® is a potential game changer for the 4.3 million men who suffer from ED in the UK and we are delighted to see it getting the recognition it deserves."
*Figures based on men reporting occasional and frequent difficulty getting or maintaining an erection, ref Kantar TNS Omnibus Survey Dec 2010 in a survey of 1,033 men. Stats are UK unless stated otherwise.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
For media enquiries please contact:
Optimum Strategic Communications
Nick Bastin / Jonathan Edwards/ Zoe Bolt / Elena Bates
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a novel treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted two Phase 3 studies using MED3000 in ED; FM57 study which enabled Futura to be granted a CE Mark in 2021 and FM71 which enabled Futura to be granted US marketing authorisation. Both studies demonstrated that MED3000 presents an effective clinically proven treatment for ED with a rapid speed of onset and a favourable benefit versus risk profile ideally suited for an 'Over the Counter' classification.
Eroxon® is FDA approved in the US, CE marked in?Europe?and UKCA marked in the?UK?as a clinically proven topical treatment for adult men with erectile dysfunction under the brand Eroxon® with a key claim of "Helps you get an erection within 10 minutes". Eroxon® is the agreed brand name in certain regions such as the EU whereas MED3000 continues to be the internal code name used by the Company and also in reference to countries where regulatory approval or commercial distribution agreements have not yet been achieved. www.eroxon.com
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com.